Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CTSV | O60911 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | CDK4 | P11802 | 1/20 | 0.40 |
| ▸ | CCND1 | P24385 | 1/20 | 0.40 |
| ▸ | FEN1 | P39748 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.39 |
| ▸ | KIF11 | P52732 | 2/20 | 0.39 |
| ▸ | RHEB | Q15382 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7517830 | 0.85 | KIF11 (0.54) | MAOANPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL7251072 | 0.84 | RHEB (0.47) | MAOANPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL7251074 | 0.81 | CTSV (0.64) | MAOASMN1; SMN2CTSVCTSLDYRK1A | |
| SCHEMBL7250601 | 0.79 | PPARG (0.56) | MAOA | |
| SCHEMBL7251253 | 0.79 | DYRK1A (0.49) | MAOAMAPTSMN1; SMN2DYRK1A | |
| SCHEMBL7250798 | 0.78 | KIF11 (0.49) | MAOANPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL1547955 | 0.78 | LSS (0.56) | NPC1RAB9A | |
| SCHEMBL533285 | 0.78 | TNKS2 (0.61) | NPC1MAPTTNKS2CDK4CCND1 | |
| SCHEMBL29533133 | 0.78 | TNKS2 (0.61) | NPC1MAPTTNKS2CDK4CCND1 | |
| SCHEMBL35210255 | 0.76 | LTA4H (0.57) | MAOANPC1MAPTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030040538-A1 | Novel substituted tricyclic compounds | ASAHI-KASEI KABUSHIKI KAISHA (JP) | 2003-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040538-A1 | Novel substituted tricyclic compounds | CPT1A, CBR1, NR1H3 | MAOA 2743/4885NPC1 65/4885MAPT 4835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.